1 min read

When Veristat Walks – Cancer Runs

LLS logoIn 1964, a child’s chance of surviving the most common form of Leukemia was 3%.  Today it has increased to 91%!  

Although progress is being made, more advances need to be made to bring treatments that are effective and minimize the long-term impact on the patient’s quality of life.  Veristat has been a contributor to this effort to bring new cures.

Veristat supports countless clients who are working on bringing new innovative therapies through the clinical development and regulatory approval process for drugs that combat the various forms of Leukemias and Lymphomas.  The most recent submission approval that Veristat supported was TIBSOVO from Agios Pharmaceuticals - to treat adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).  

LTN photoFor the third consecutive year, Veristat is walking in the Light the Night Boston Walk for the Leukemia and Lymphoma Society  and is collecting donations toward finding a cure to Leukemia, Non-Hodgkin’s Lymphoma and other blood cancers.   LLS uses the funds that are raised to help provide education and support services for patients, their families, and caregivers.


Make A Donation To Support Team Veristat Today

Help us make Cancer run!   Donate today to support Team Veristat in our drive for a world free of blood cancers.


Donate Today


Key Related Services:


Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)

The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of...

Read More

1 min read

On-Demand Webinar: Orphan Drug Designation - The Considerations, The Rewards, and How They Differ Between The US and Europe

Did you know approximately 1 in 10 Americans are affected by a rare disease or condition according to the National Institutes of Health (NIH)? That’s...

Read More

Rolling Review mechanisms and CMAs (Conditional Marketing Authorisations) have made it possible to speed up the approval of treatments against Covid-19

GENESIS BIOMED recently interviewed Xavier Luria, former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and now...

Read More